Genmab’s shares rose 5.7% post-earnings, reflecting investor approval of strong revenue growth and robust commercial execution, particularly driven by the significant sales acceleration of EPKINLY and expanding late-stage pipeline momentum.
- Total revenue increased 25% year-over-year, underpinned by broad portfolio growth.
- EPKINLY sales rose 48% year-over-year to $312 million in H1, with new patient starts and site activations driving growth, especially in the US.
- Proprietary product portfolio sales grew 37% to $396 million, reflecting solid commercial traction.
- Pipeline progress includes positive Phase III results for EPCORE DLBCL-4 and European approval of TEPKINLY, signaling clinical and regulatory advances.
- Genmab confirmed ongoing late-stage development progress with multiple upcoming Phase III readouts in late 2026 and early 2027 across key indications.
Community Discussion